Frost & Sullivan

AUGUST 29, 2024

As of April 2023, the global pharmaceutical R&D pipeline has over 6000 molecules in active clinical development phase, showing a 5.8% growth from 2023 to 2024. increase from 2022. However, the pharma/biopharma industry overall shows stagnant R&D activity. Total R&D expenditure is approximately $276.81

Biopharma 52

Biopharma Biotechnology Contract research organization Utilities 52

Frost & Sullivan

MARCH 22, 2024

As of April 2023, the global pharmaceutical R&D pipeline has over 6000 molecules in active clinical development phase, showing a 5.8% growth from 2023 to 2024. What is driving transformation in the pharma industry? increase from 2022. However, the pharma/biopharma industry shows overall stagnant R&D activity.

Ecosystems 52

Ecosystems Biopharma Biotech Contract research organization 52

Frost & Sullivan

APRIL 25, 2023

April 25, 2023 – Frost & Sullivan researched the contract research organizations industry and, based on its analysis results, recognizes Emmes with the 2023 Global Competitive Strategy Leadership Award. SAN ANTONIO, TX.

Biopharmaceuticals 52

Biopharmaceuticals Biopharma Biotechnology Contract research organization 52

Frost & Sullivan

FEBRUARY 15, 2024

Let us coach you on your transformational journey, while we actively support you in fostering collaborative initiatives within your industry’s ecosystem. Small- to mid-sized pharma/biotech players in APAC are rivaling Europe in clinical trials through multiple CRO partnerships in the region, tapping into a population-rich landscape.

Ecosystems 40

Ecosystems Contract research organization Biotech Utilities 40

Frost & Sullivan

OCTOBER 11, 2024

San Antonio, TX — 14 th October 2024 — Frost & Sullivan recently conducted an in-depth analysis of the biotech contract research organization (CRO) industry and based on its findings, has awarded Novotech the 2024 Global Company of the Year Award.

Biotech 52

Biotech Contract research organization Strategic partnership Collaboration 52